EMYRIA LIMITED — Capital/Financing Update 2020

Jun 21, 2020

ASX/Media Release

==> picture [170 x 82] intentionally omitted <==

22/06/2020

Emerald’s digital health platform expands with new technology

Highlights

• Emerald integrates a world leading vital signs capture technology using mobile phones into its RealWorld Evidence platform via an agreement with Artificial Intelligence technology company Binah.ai

• Emerald selected by Linear Clinical Research to remotely monitor 150 participants involved in a twoyear COVID-19 vaccine trial

• Emerald’s expanded remote monitoring digital health platform, using the Binah.ai technology and to be called Sentinel Plus, could support companies, Universities and Governments to monitor the health of their personnel remotely, as reopening rolls out internationally, subject to successful validation of the platform

• Emerald is targeting organisations in Australia and the US for implementation of Sentinel Plus as organisations return to work and school

Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence company that develops remote patient monitoring technology underpinned by a clinical services model, is pleased to announce it has signed new agreements that will greatly enhance its current data capture technology platform and support the launch of a new digital health and clinical monitoring service to be called “Sentinel Plus”.

Emerald has secured an agreement with artificial intelligence (AI) technology company, Binah.ai, to incorporate Binah’s world leading smartphone technology into Emerald’s Real-World Evidence (RWE) engine. The technology harnesses video and AI to support the capture of vital signs in a completely contactless manner by measuring the change in colour (micro-blushes) of the skin, pixel by pixel, in less than a minute. Vital signs (such as heart rate and blood oxygen levels) provide clinically relevant data but are often difficult to obtain from patients remotely.

Currently at an early stage further testing and validation of the Binah technology is planned in the coming month to integrate the Binah.ai technology with Emerald’s current RWE platform. If successful Emerald’s platform will then be able to capture and provide live reports on vital signs measurements using just the camera on a user’s mobile phone. No other hardware (such as pulse oximeters or heart rate monitors) is required.

The enhanced platform will allow Emerald to incorporate contactless vital signs alongside other clinical and symptom data already collected, through Emerald’s current RWE engine. Emerald’s current RWE engine is the core that takes patient information to determine risk profiles and inform clinical decisions by Emerald’s clinical team. From a regulatory point of view, the Binah technology adds vital sign data to the comprehensive set of clinical assessments already performed by Emerald’s healthcare professionals and is considered a clinical decision support aid. Sentinel Plus may support back to work and back to school initiatives. Emerald will pay Binah a subscription fee for user licences and has acquired the software developer kit to enable multiple applications.

Emerald has been using its current RWE platform for COVID symptom monitoring across its patient population since April and has been successfully supporting other clinical trials since founding. Emerald has been engaged by Linear Clinical Research (Linear) to support the remote evaluation of more than 150 healthy volunteer trial participants over a two-year period for a Phase 1 COVID-19 vaccine study that Linear

==> picture [169 x 82] intentionally omitted <==

is set to announce shortly. Emerald plans to utilise the Binah.ai technology as part of this monitoring service. Emerald will be paid a monthly retainer of $5,000 per month as well as separate consultation and data management fees for each required clinical review on a per patient basis. The Linear Agreement is subject to a review after an initial 3-month period and the study is scheduled to continue through to December 2022. Dr Michael Winlo, CEO Emerald Clinics is also a Director of Linear.

Subject to successful validation Emerald is also targeting other potential customers for Sentinel Plus in anticipation of demand for a clinician-monitored service for remote health monitoring. Organisations are currently reviewing a range of tools to enable monitoring of employees and students as they return to work and school, ranging from paper driven surveys to integrated software tools like Sentinel Plus. The ability to use mobile phones instead of costly and scarce hardware to capture vital signs and symptom information, provides an opportunity to scale remote care in a patient friendly and cost effective manner.

“These collaborations greatly extend the reach and impact of Emerald’s digital health Real-World Evidence engine that we have built over several years as well as expand our commercial offerings with Sentinel Plus,” said Emerald Clinics CEO Dr Michael Winlo.

“Our RWE engine is the core of Emerald and it learns from each individual patient that we monitor or treat.”

“The platform also provides an evidence-based health monitoring service for businesses of all shapes and sizes, and produces relevant, accurate and actionable health information. It will empower businesses to get back to work with a greater level of comfort, knowing that proactive monitoring measures are in place to protect the health and safety of their workforce. We anticipate that this technology will greatly support workforce culture, productivity and overall economic performance.”

The latest developments follow Emerald’s appointment last month as Program Manager for the development of a national clinical data and analytics platform of COVID-19 patient cases in a partnership between NSW Health, Queensland Health, QUT, the University of Sydney, and Monash University and the Federal Government.

Emerald has licensed the Binah.ai technology for a fee of USD100,000.

Release authorised by:

Dr Michael Winlo, CEO and Managing Director

For further information:

Dr Michael Winlo Matt Wright CEO Media/investor relations (08) 6559 2800 +61 (0) 451 896 420 investors@emeraldclinics.com.au matt@nwrcommunications.com.au

==> picture [169 x 82] intentionally omitted <==

About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald’s evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.